NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$84.22

+0.24 (+0.29%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $82.63
▼
$85.21
50-Day Range: $71.03
▼
$84.27
52-Week Range: $47.67
▼
$85.65

Volume: 97,870 shs
Average Volume: 199,046 shs
Market Capitalization: $2.17 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $106.75

Institutional Ownership

Krystal Biotech MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 26.8% Upside
$106.75 Price Target
Short Interest: Bearish
5.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.84
Based on 5 Articles This Week
Insider Trading: Selling Shares
$5.85 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.36) to ($4.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

275th out of 1,049 stocks

Biological Products, Except Diagnostic Industry

48th out of 170 stocks

3.3

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $106.75, Krystal Biotech has a forecasted upside of 26.8% from its current price of $84.22.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.44% of the float of Krystal Biotech has been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 6.5.
Change versus previous month
Short interest in Krystal Biotech has recently increased by 14.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

3.2

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Krystal Biotech this week, compared to 1 article on an average week.
Search Interest
9 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,848,121.00 in company stock.
Percentage Held by Insiders
17.80% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.80% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow in the coming year, from ($5.36) to ($4.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

January 29, 2023 | americanbankingnews.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

January 23, 2023 | americanbankingnews.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 10.2% in December

January 29, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 22, 2023 | americanbankingnews.com

Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 22,148 Shares of Stock

January 20, 2023 | seekingalpha.com

Krystal Biotech: Reached My Price Target, Waiting For A Drop

January 20, 2023 | americanbankingnews.com

Krystal Biotech, Inc. (NASDAQ:KRYS) CEO Krish S. Krishnan Sells 22,149 Shares

January 18, 2023 | finance.yahoo.com

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

January 10, 2023 | msn.com

FDA extends review of Krystal's topical gene therapy for skin disorder citing manufacturing data

January 29, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 9, 2023 | finance.yahoo.com

Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA

January 9, 2023 | markets.businessinsider.com

Krystal Biotech Announces FDA's 3-Month Extension Of BLA PDUFA Date And Regulatory Update For B-VEC

January 9, 2023 | finance.yahoo.com

Krystal Biotech’s stock is down on delayed PDUFA date

January 9, 2023 | finance.yahoo.com

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

December 16, 2022 | finance.yahoo.com

BofA Securities: The most promising biotech stocks in 2023

December 15, 2022 | finance.yahoo.com

Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine

December 14, 2022 | finance.yahoo.com

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

December 12, 2022 | finance.yahoo.com

12 Best Small-Cap Healthcare Stocks To Buy Now

December 6, 2022 | finance.yahoo.com

2 Risky Stocks That Could Soar in 2023

December 5, 2022 | finance.yahoo.com

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

December 1, 2022 | finance.yahoo.com

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

November 23, 2022 | finance.yahoo.com

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

November 17, 2022 | msn.com

Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles

November 17, 2022 | finance.yahoo.com

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

November 13, 2022 | seekingalpha.com

Vertex: High Growth For Years Ahead

November 7, 2022 | thestreet.com

Krystal Biotech Needs to Feed the Goldfish in 2023

November 7, 2022 | finanznachrichten.de

Krystal Biotech, Inc.: Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

November 7, 2022 | msn.com

Recap: Krystal Biotech Q3 Earnings

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings: 11/07/2022
Today: 1/29/2023
Next Earnings (Estimated): 2/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 119
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $106.75
High Stock Price Forecast: $133.00
Low Stock Price Forecast: $74.00
Forecasted Upside/Downside: +26.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -18.68%
Return on Assets: -17.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.18
Quick Ratio: 14.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $26.69 per share
Price / Book: 3.16

Miscellaneous

Outstanding Shares: 25,750,000
Free Float: 21,165,000
Market Cap: $2.17 billion
Optionable: Not Optionable
Beta: 0.84

Key Executives

Mr. Krish S. Krishnan M.B.A. (Age 58)
M.S., Founder, Chairman, Pres & CEO
Comp: $1.01M

Ms. Suma M. Krishnan (Age 58)
Founder, COO, Pres of R&D and Director
Comp: $708.56k

Ms. Kathryn A. Romano (Age 41)
Exec. VP & Chief Accounting Officer
Comp: $452.43k

Dr. Andreas C. Orth (Age 53)
Exec. VP & Chief Commercial Officer
Comp: $549.17k

Ms. Gloria Lin
Accounting Mang.

Mr. Ram Kamineni
Sr. VP of CMC & Technical Operations

Ms. Meg Dodge
VP of Investor Relations & Corp. Communications

Mr. David Glynn
Gen. Counsel, Commercial & Compliance

Mr. John Karakkal
VP of North American Sales & Marketing

Ms. Katherine Tuminello
HR & Office Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price forecast for 2023?: 3 brokers have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price forecasts range from $74.00 to $133.00. On average, they anticipate the company's stock price to reach $106.75 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2023?: Krystal Biotech's stock was trading at $79.22 on January 1st, 2023. Since then, KRYS shares have increased by 6.3% and is now trading at $84.22.
View the best growth stocks for 2023 here.
Are investors shorting Krystal Biotech?: Krystal Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,130,000 shares, an increase of 14.4% from the December 31st total of 988,100 shares. Based on an average trading volume of 174,600 shares, the days-to-cover ratio is currently 6.5 days. Currently, 5.4% of the shares of the company are short sold.
View Krystal Biotech's Short Interest.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, November, 7th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.23) by $0.06.

What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).
When did Krystal Biotech IPO?: (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
What is Krystal Biotech's stock symbol?: Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
Who are Krystal Biotech's major shareholders?: Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.18%) and Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Krystal Biotech's stock price today?: One share of KRYS stock can currently be purchased for approximately $84.22.
How much money does Krystal Biotech make?: Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.17 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.
How many employees does Krystal Biotech have?: The company employs 119 workers across the globe.
How can I contact Krystal Biotech?: Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 1/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Krystal Biotech - KRYS Stock Forecast, Price & News

Krystal Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Krystal Biotech (NASDAQ:KRYS) Stock

KRYS Stock News Headlines

KRYS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KRYS Stock - Frequently Asked Questions

Overall MarketRank^™